Remote ischaemic Conditioning After Stroke Trial - 3

Remote Ischaemic Conditioning After Stroke Trial (ReCAST- 3)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN63231313

Enrollment

1300

Registered

2020-04-20

Start date

2024-01-01

Completion date

Unknown

Last updated

2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adults with acute ischaemic stroke presenting in Emergency Departments and Stroke Units in the UK Circulatory System Hyperacute ischaemic stroke

Interventions

Current interventions as of 09/04/2025: Participants will be allocated to either receive the intervention or the comparator. The intervention/remote ischaemic conditioning group will receive 4 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current participant inclusion criteria as of 09/04/2025: 1. Acute ischaemic stroke 2. 4 at randomisation 5. Aged >18 years

Exclusion criteria

Exclusion criteria: Current participant exclusion criteria as of 09/04/2025: 1. Pre-morbid dependency (modified Rankin Scale, mRS>3) 2. Systolic BP =80 mmHg 3. Spontaneous intracerebral haemorrhage 4. Haemorrhagic transformation of infarction PH2 if known before randomisation (not excluded or withdrawn if occurs after randomisation) 5. Dementia - if the patient had a pre-existing diagnosis 6. Coma (GCS 3) 2. Systolic BP =80 mmHg 3. Spontaneous intracerebral haemorrhage 4. Haemorrhagic transformation of infarction PH2 if known before randomisation (not excluded or withdrawn if occurs after randomisation) 5. Dementia - if the patient had a pre-existing diagnosis 6. Coma (GCS 3) 2. Spontaneous intracerebral haemorrhage 3. Haemorrhagic transformation of infarction PH2 4. Dementia 5. Coma (GCS 3) 2. Spontaneous intracerebral haemorrhage 3. Dementia 4. Coma (GCS 3) 2. Spontaneous intracerebral haemorrhage 3. Dementia 4. Coma (GCS 7 days) nitrate therapy 10. Receiving treatment for diabetes 11. Pregnancy

Design outcomes

Primary

Measure	Time frame
Death or dependency assessed by the modified Rankin Scale (mRS) ordinal shift analysis recorded using central blinded telephone follow-up at 90 days.	—

Secondary

Measure	Time frame
1. Adverse events including: death, neurological deterioration, intracranial haemorrhage, systemic embolism, and other serious adverse events measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 2. Cerebrovascular events measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 3. Major adverse cardiac and cerebral events measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 4. Acute kidney injury measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 5. Disability measured through responses to central blinded telephone follow-up at 90 days 6. Cognition measured through responses to central blinded telephone follow-up at 90 days 7. Mood measured through responses to central blinded telephone follow-up at 90 days 8. Frailty measured through responses to central blinded telephone follow-up at 90 days 9. Quality of life measured through responses to central blinded telephone follow-up at 90 days	—

Measure

Time frame

1. Adverse events including: death, neurological deterioration, intracranial haemorrhage, systemic embolism, and other serious adverse events measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 2. Cerebrovascular events measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 3. Major adverse cardiac and cerebral events measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 4. Acute kidney injury measured through clinical assessment at 2 and 4 days, patient notes at discharge, and responses to central blinded telephone follow-up at 90 days 5. Disability measured through responses to central blinded telephone follow-up at 90 days 6. Cognition measured through responses to central blinded telephone follow-up at 90 days 7. Mood measured through responses to central blinded telephone follow-up at 90 days 8. Frailty measured through responses to central blinded telephone follow-up at 90 days 9. Quality of life measured through responses to central blinded telephone follow-up at 90 days

—

Countries

England, Northern Ireland, Scotland, United Kingdom, Wales

Contacts

Public ContactDiane Havard

diane.havard@nottingham.ac.uk+44 0115 823 1775

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026